Syntopix signs exclusive evaluation deal
Pharmaceutical R&D company Syntopix Group, which focuses on the topical treatment of dermatological diseases, says it has signed an exclusive evaluation agreement with an as yet unnamed major global consumer healthcare company to develop cosmetic products. Under the agreement, Syntopix will make its library of compounds available for evaluation and for potential development into commercial products.
Pharmaceutical R&D company Syntopix Group, which focuses on the topical treatment of dermatological diseases, says it has signed an exclusive evaluation agreement with an as yet unnamed major global consumer healthcare company to develop cosmetic products. Under the agreement, Syntopix will make its library of compounds available for evaluation and for potential development into commercial products.
The financial details of the agreement are undisclosed, although Syntopix will receive an upfront payment at the start of the exclusivity period and further payments for any compounds subject to additional evaluation.